AU4084599A - Resveratrol inhibition of myeloperoxidase - Google Patents

Resveratrol inhibition of myeloperoxidase

Info

Publication number
AU4084599A
AU4084599A AU40845/99A AU4084599A AU4084599A AU 4084599 A AU4084599 A AU 4084599A AU 40845/99 A AU40845/99 A AU 40845/99A AU 4084599 A AU4084599 A AU 4084599A AU 4084599 A AU4084599 A AU 4084599A
Authority
AU
Australia
Prior art keywords
myeloperoxidase
resveratrol
inhibition
resveratrol inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU40845/99A
Inventor
Robert A Floyd
Kenneth L. Hensley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU4084599A publication Critical patent/AU4084599A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
AU40845/99A 1998-05-18 1999-05-18 Resveratrol inhibition of myeloperoxidase Withdrawn AU4084599A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8582198P 1998-05-18 1998-05-18
US60085821 1998-05-18
PCT/US1999/010969 WO1999059561A2 (en) 1998-05-18 1999-05-18 Resveratrol inhibition of myeloperoxidase

Publications (1)

Publication Number Publication Date
AU4084599A true AU4084599A (en) 1999-12-06

Family

ID=22194174

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40845/99A Withdrawn AU4084599A (en) 1998-05-18 1999-05-18 Resveratrol inhibition of myeloperoxidase

Country Status (2)

Country Link
AU (1) AU4084599A (en)
WO (1) WO1999059561A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
IT1302365B1 (en) 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa USE OF CARNITINE AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF BRAIN ALTERATIONS
WO2000038620A2 (en) * 1998-12-24 2000-07-06 1333366 Ontario Inc. A composition useful to treat periodontal disease
US6716883B1 (en) 1998-12-24 2004-04-06 1333366 Ontario Inc. Composition useful to treat periodontal disease
PE20010540A1 (en) * 1999-07-30 2001-05-15 Procter & Gamble COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
JP4880847B2 (en) * 1999-12-06 2012-02-22 ウェリケム，バイオテック インコーポレーテッド Anti-inflammatory and psoriasis treatments and protein kinase inhibition with hydroxylstilbene and novel stilbene derivatives and analogs
IT1318425B1 (en) * 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro USE OF RESVERATROL FOR THE TREATMENT OF DESQUAMATIVE ECZEMA, ACNE AND PSORIASIS.
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US20020173511A1 (en) * 2000-11-08 2002-11-21 Wurtman Richard J. Serotonergic compositions and methods for treatment of mild cognitive impairment
FR2816843B1 (en) * 2000-11-23 2006-10-27 Actichem INHIBITORS OF ENZYME 5 ALPHA-REDUCTASE
EP2060255B1 (en) * 2001-11-02 2013-06-05 The Regents of the University of California Compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
WO2003077900A1 (en) 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
JP2005533042A (en) * 2002-06-10 2005-11-04 オクラホマ　メディカル　リサーチ　ファウンデーション Methods for using linked bis (polyhydroxyphenyl) and its O-alkyl derivatives in the treatment of inflammatory conditions of the central nervous system
EP1633208A1 (en) 2003-05-27 2006-03-15 DSM IP Assets B.V. Novel nutraceutical compositions and use thereof
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
JP4903569B2 (en) * 2003-09-12 2012-03-28 アクセス ビジネス グループ インターナショナル エルエルシー Cytokine modulators and related uses
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
JP2008527002A (en) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders
FR2882502B1 (en) * 2005-02-25 2007-04-20 Claude Bonne FOOD SUPPLEMENTS FOR PATIENTS WITH PSORIASIS
WO2006102407A2 (en) 2005-03-23 2006-09-28 Children's Medical Center Corporation Orthotic device for preventing and/or correcting deformational posterior plagiocephaly
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
US8883218B2 (en) 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
US9095598B2 (en) * 2010-12-28 2015-08-04 The Board Of Trustees Of The University Of Arkansas Stilbenoid derivatives and their uses
US9044491B2 (en) * 2010-12-28 2015-06-02 The Board Of Trustees Of The University Of Arkansas Method for improving blood flow using stilbenoid derivatives
UA108713C2 (en) 2011-11-11 2015-05-25 2-Thiopyrimidinones
CN102816090A (en) * 2012-09-10 2012-12-12 四川大学 Carbamate compounds, preparation method and application thereof
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
WO2016179328A1 (en) 2015-05-05 2016-11-10 Children's Medical Center Corporation Devices and methods for supporting and containing premature babies and small-for-age infants
MX2017014128A (en) 2015-05-05 2018-03-15 Pfizer 2-thiopyrimidinones.
CN107666902B (en) 2015-05-21 2021-09-21 德玛万科学有限责任公司 Topical pharmaceutical composition
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
JP6912664B2 (en) 2017-11-10 2021-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー Process for preparing tapinarov
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6160609A (en) * 1984-08-31 1986-03-28 Green Cross Corp:The Lipoxygenase inhibitor
JPS61171427A (en) * 1985-01-24 1986-08-02 Osaka Chem Lab Substance for preventing thrombosis or the like
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
JPH04159280A (en) * 1990-10-24 1992-06-02 Tsumura & Co 5-lipoxygenase inhibitor containing hydroxystilbene-based compound as active ingredient
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
IT1276225B1 (en) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ALKANOYL L-CARNITINE IN ASSOCIATION WITH RESVERATROL OR ITS DERIVATIVES USEFUL FOR

Also Published As

Publication number Publication date
WO1999059561A2 (en) 1999-11-25
WO1999059561A3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
AU4084599A (en) Resveratrol inhibition of myeloperoxidase
AU5100599A (en) Egf-genistein for prevention of restenosis
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU2190700A (en) Tubulin-binding agents
AU3300599A (en) Per-method designation of security requirements
AU4580599A (en) Stable no-delivering compounds
AU3898999A (en) Aloe pectins
AU3052899A (en) Determination of apnea type
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU2863899A (en) New compounds
AU4598199A (en) Skateboard
AU1424200A (en) Compounds
AU4501699A (en) Aminoazole compounds
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU1434500A (en) Compounds
AU1550800A (en) Abs-moulding compounds with an improved combination of properties
AU5290999A (en) Simplified window-raiser -
AU2333099A (en) Aryloxyanilides and related compounds
AU1055600A (en) Facilitating ablutions
AU2192199A (en) Magnetron
AU5998199A (en) New bis-benzimidazoles
AU5622599A (en) Use of 5-amino-pyrazol-derivatives for combating micro-organisms
AU1775500A (en) Circuit-breaker